Biocon Limited has entered into a global patent settlement and licence agreement with Genentech, a subsidiary of Roche, resolving pending disputes over Pebrilzo, its biosimilar to Perjeta (pertuzumab), a biologic medicine used to treat HER2-positive breast cancer. The agreement establishes launch timelines for the drug